Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. develops, manufactures and commercializes neuromodulation medical devices for cardiovascular disease. Its Barostim therapy is an implantable system that delivers electrical pulses to carotid baroreceptors to rebalance autonomic nervous system signaling and improve symptoms in heart failure patients.
Company updates commonly cover Barostim commercialization in the United States and Europe, FDA approval and Breakthrough Device history, CE Mark status for heart failure and resistant hypertension in the European Economic Area, clinical data from heart failure studies, reimbursement and coding developments, quarterly operating results, financing activity and board governance matters.
CVRx (NASDAQ: CVRX) announced that Devoted Health has implemented a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026. Devoted Health covers approximately 466,000 Medicare Advantage members across 29 states and is the eighth largest Medicare Advantage insurer in the U.S.
The policy covers Barostim for patients within its current FDA-approved indication and for patients enrolled in the BENEFIT-HF heart failure trial. Together with Humana’s existing Barostim coverage, these policies represent about 21% of Medicare Advantage enrollment. Additional 2026 milestones include the start of Category I CPT codes for the Barostim procedure and CMS Category B IDE coverage for BENEFIT-HF trial patients.
CVRx (NASDAQ: CVRX) minority shareholder Jorey Chernett, founder of Pointillist Family Office and owner of more than 5.5% of CVRx shares, delivered a letter to the CVRx board on August 24, 2026. He urges the board to begin an immediate, formal process to sell the company to a strategic acquirer, highlighting the Barostim product as a key asset.
Chernett asks the board to retain an independent financial advisor, prioritize a sale within a broader strategic review, cut executive compensation and G&A, suspend incremental standalone spending, and publicly commit to a defined process and timeline.
CVRx (NASDAQ: CVRX) announced that Chief Revenue Officer Robert John will depart the company, effective immediately. Paul Verrastro, who has over 30 years of medical device sales and marketing experience and more than five years at CVRx, has been appointed Interim Head of Sales.
According to CVRx, Verrastro will lead the sales organization while a search is conducted for a permanent successor. Management linked the leadership change to a revised commercial outlook and a need to improve commercial execution, while emphasizing Verrastro’s familiarity with the business, customers and commercial strategy.
CVRx (NASDAQ: CVRX) reported second quarter 2026 revenue of $15.7 million, up 16% year over year, driven by U.S. revenue of $14.8 million, up 21%. Gross profit was $13.7 million with gross margin improving to 87% from 84%. Net loss narrowed slightly to $14.0 million, or $0.53 per share.
U.S. revenue units rose to 466 and active implanting centers reached 258, while European revenue declined 31% to $0.9 million. Humana issued a Medicare Advantage coverage policy for Barostim effective May 1, 2026. CVRx now guides 2026 revenue to $58–$60 million, gross margin of 86–87%, operating expenses of $99–$101 million, and Q3 2026 revenue of $13.5–$14.5 million.
CVRx (NASDAQ: CVRX), a commercial-stage medical device company focused on neuromodulation therapies for cardiovascular disease, announced that its management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, starting at 1:00 p.m. ET.
A live webcast of the presentation and a time-limited archived replay will be accessible via the company’s investor relations website at ir.cvrx.com.
CVRx (NASDAQ: CVRX) announced it will release its second quarter 2026 financial and operating results after market close on Thursday, August 6, 2026. The company will host a conference call to review the results at 4:30 p.m. Eastern Time, with a live webcast available on its investor relations website.
CVRx (NASDAQ: CVRX) announced a Chief Financial Officer transition. Jared Oasheim, CFO since 2015, will step down to pursue other opportunities, remain until a successor is appointed, and advise through February 2027. CVRx has started a search for a new CFO.
President and CEO Kevin Hykes highlighted Oasheim’s role in leading the IPO and building the finance organization. CVRx also confirmed that Hykes and Oasheim will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, with a live webcast and archived replay.
CVRx (NASDAQ: CVRX) announced that its management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Wednesday, June 10, 2026, at 8:00 a.m. ET.
A live webcast and limited-time archived replay will be available at ir.cvrx.com.
CVRx (NASDAQ: CVRX) announced that its management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026, at 10:40 a.m. CT. A live webcast and limited-time archived replay will be available at ir.cvrx.com.
CVRx (NASDAQ: CVRX) announced that Humana issued a Medicare Advantage coverage policy for its Barostim therapy, effective May 1, 2026. Humana covers about 5.2 million Medicare Advantage members across 46 states.
The policy applies to Barostim’s current FDA-approved indication and to patients in the BENEFIT-HF heart failure trial. CVRx calls this the first coverage policy for Barostim. It follows new Category I CPT codes and CMS Category B IDE coverage for BENEFIT-HF patients, both effective January 1, 2026.